FDA grants priority review to durvalumab plus enfortumab vedotin for cisplatin-ineligible MIBC based on positive phase 3 VOLGA data.
|Videos|May 23, 2011
Juanita Madison on Handling the Provenge Process
Author(s)Juanita Madison, MN, RN
Juanita Madison from the Seattle Cancer Care Alliance on Handling the Provenge Treatment Process
Advertisement
Lead researcher Juanita Madison, MN, RN, AOCN from the Seattle Cancer Care Alliance (SCCA) of a multidisciplinary study looking at Provenge discusses handling the treatment process. Using the Plan-Do-Study-Act quality-improvement model the multidisciplinary task-force devised, implemented, and revised a Provenge treatment strategy.
Advertisement
Related to this article
The CHMP recommended perioperative pembrolizumab plus enfortumab vedotin for resectable muscle-invasive bladder cancer.
Advertisement
Advertisement
Trending on OncLive
1
Ifinatamab Deruxtecan BLA Voluntarily Withdrawn in Previously Treated Extensive-Stage SCLC
2
FDA Approves Lirafugratinib for Pretreated, Locally Advanced or Metastatic Cholangiocarcinoma
3
Long-Term PERSEUS Data Confirm Durable PFS Benefit With D-VRd in Transplant-Eligible Newly Diagnosed Myeloma
4
Dr Voorhees on Eligibility Criteria for the CERVINO Trial in Multiple Myeloma
5